Literature DB >> 72602

Specificity of antisera produced against bleomycin.

J E Strong, A Broughton, S T Crooke.   

Abstract

The specificity of antisera produced in a goat or rabbit for use in bleomycin radioimmunoassay has been examined using competitive experiments employing several bleomycin analogs. These studies demonstrate that the antiserum distinguished alterations in both the nucleus and the terminal structure of the molecule. Removal of the terminal structure or addition of an aminosugar moiety in the bleomycin nucleus resulted in a significant decrease in immunoreactivity. Antisera produced in goat and rabbit hosts had different specificity for the terminal structure. The goat antisera demonstrated greater specificity for the terminal side chain than the rabbit antisera although this may not reflect a species-related event.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 72602

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  4 in total

1.  Bleomycin pharmacokinetics in man. I. Intravenous administration.

Authors:  D S Alberts; H S Chen; R Liu; K J Himmelstein; M Mayersohn; D Perrier; J Gross; T Moon; A Broughton; S E Salmon
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

Review 2.  The practical benefits of pharmacokinetics in the use of antineoplastic agents.

Authors:  C Erlichman; R C Donehower; B A Chabner
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

3.  Pharmacokinetics of bleomycin in man. III. Bleomycin 57Co Vs bleomycin.

Authors:  D S Alberts; H S Chen; J M Woolfenden; T E Moon; S Y Chang; J N Hall; K J Himmelstein; J Gross; S E Salmon
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

4.  Bleomycin clinical pharmacology by radioimmunoassay.

Authors:  S W Hall; J E Strong; A Broughton; M L Frazier; R S Benjamin
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.